Loading ......
Antibody-drug conjugates (ADCs) were designed to solve a long-standing problem in cancer treatment: how to deliver extremely potent cytotoxic drugs to tumors while limiting exposure in healthy tissues. Yet the antibody is only one part of the equation. The linker controls when and where the drug is released, while the payload determines what happens after the ADC reaches the target cell. As ADC development has matured, the choice of payload has therefore become a strategic decision rather than a simple chemistry preference. MMAE and DXd illustrate two particularly important approaches. MMAE, or monomethyl auristatin E, is a highly potent microtubule-disrupting payload that has been incorporated into multiple clinically successful ADCs. DXd, the exatecan-derived payload used in trastuzumab deruxtecan and other ADC programs, inhibits topoisomerase I and damages DNA during replication. Both can deliver potent antitumor activity, but they create very different pharmacological profiles. The question is therefore not simply whether DXd is "better" than MMAE. The more useful question for ADC developers is whether MMAE-based designs can still offer a competitive therapeutic window when newer topoisomerase I inhibitor payloads have demonstrated strong activity in solid tumors. The answer is yes—but only when the antibody, linker, conjugation strategy, payload exposure and target biology are engineered as one integrated system.

MMAE belongs to the auristatin family and acts primarily by interfering with microtubule dynamics. After intracellular release, it binds tubulin and disrupts the machinery required for normal cell division, producing cell-cycle arrest and ultimately apoptotic cell death. Its extreme potency is one of the reasons auristatins remain attractive for ADC development: an ADC does not need to deliver a conventional chemotherapeutic dose to every tumor cell for the payload to have a meaningful effect.
A particularly important characteristic of MMAE is its membrane permeability. Once released, the payload can diffuse beyond the originally targeted cell and contribute to a bystander effect. This can be valuable in heterogeneous tumors in which antigen expression is uneven, because not every neighboring cancer cell needs to internalize the ADC directly. The same property, however, can become a liability if premature or extracellular release occurs. Payload leakage can increase exposure to healthy tissues and narrow the therapeutic window.
MMAE also benefits from extensive development experience. As one of the most frequently used ADC payloads, it has generated substantial knowledge around linker chemistry, conjugation, pharmacokinetics and toxicity management. This accumulated experience can reduce some of the uncertainty associated with developing a new ADC platform. The continued clinical use of MMAE-containing ADCs demonstrates that the payload is far from obsolete.
DXd represents a different pharmacological strategy. It is an exatecan derivative that inhibits topoisomerase I, interfering with the DNA replication process and ultimately generating lethal DNA damage. This mechanism differs fundamentally from the microtubule disruption produced by MMAE, which means the two payloads can behave differently depending on tumor proliferation, DNA-repair capacity, intracellular trafficking and resistance mechanisms.
DXd has become especially influential because it is associated with ADC designs capable of producing substantial activity across a range of solid tumors. Trastuzumab deruxtecan, for example, contains approximately eight deruxtecan molecules per antibody and uses a protease-cleavable tetrapeptide linker. This relatively high drug loading, together with the properties of the released payload, contributes to a strong pharmacological effect and a pronounced bystander component.
The clinical momentum behind DXd is also difficult to ignore. In 2026, the FDA expanded trastuzumab deruxtecan into two additional HER2-positive early-stage breast cancer settings, demonstrating how rapidly DXd-based ADC technology continues to influence treatment strategies.
But DXd is not a universal solution. Its potency and broad tissue activity do not eliminate the fundamental challenges of ADC development. Trastuzumab deruxtecan, for example, carries a boxed warning for interstitial lung disease and pneumonitis, including fatal cases. This is an important reminder that increasing payload delivery does not automatically produce a wider therapeutic window.
Comparing MMAE and DXd solely by cytotoxic potency can lead to the wrong development decision. An ADC is a multicomponent therapeutic system, and the observed efficacy depends on how efficiently the entire construct moves through circulation, binds its target, enters the tumor, undergoes intracellular processing and releases an active payload.
MMAE offers a well-established microtubule mechanism and strong membrane permeability, making it particularly attractive when bystander killing is important. DXd provides a topoisomerase I mechanism and has become highly effective in ADC formats designed for substantial payload delivery. Recent experimental work comparing anti-tubulin and topoisomerase I payloads also suggests that DXd can show stronger antitumor activity in some experimental settings, but such comparisons should not be interpreted as proof that one payload will outperform the other in every ADC.
The tumor itself can ultimately determine the winner. A rapidly proliferating tumor may be highly vulnerable to disruption of mitosis, while tumors with particular DNA-repair vulnerabilities may respond differently to a topoisomerase I inhibitor. Antigen density, internalization rate, lysosomal processing, drug efflux and the spatial distribution of target-positive and target-negative cells can further alter the relative performance of each payload.
One of the most overlooked issues in an MMAE-versus-DXd comparison is that payload performance cannot be separated from linker design. A highly potent payload is only useful if the ADC remains sufficiently stable in circulation and releases the active drug efficiently after reaching the intended intracellular environment.
For MMAE, cleavable linkers have been extensively explored because controlled intracellular release can generate membrane-permeable MMAE and enhance bystander killing. The challenge is maintaining adequate plasma stability while achieving efficient release inside target cells.
DXd-based ADCs have similarly relied on carefully engineered cleavable linkers. The current generation of designs demonstrates how linker-payload combinations can support high drug loading without simply accepting uncontrolled systemic release. This is one reason why payload comparisons based only on the free drug can be misleading: the pharmacology of an ADC is determined by the complete antibody-linker-payload architecture.
MMAE can still compete, but the development strategy has to be more sophisticated than simply attaching a familiar payload to a new antibody. The strongest opportunity lies in situations where MMAE's characteristics complement the biology of the target.
For targets with efficient internalization, appropriate intracellular processing and heterogeneous expression, the membrane-permeable nature of MMAE can be valuable. It can also provide a mechanism of action that differs from topoisomerase I inhibitors, creating opportunities for tumor types or treatment settings in which resistance to DNA-damaging payloads is problematic.
MMAE may also remain attractive when developers prioritize a well-understood payload platform and want to optimize other components of the ADC. Site-specific conjugation, controlled DAR, improved linker stability and target selection can potentially compensate for limitations that might otherwise be attributed to the payload itself. In other words, an ADC should not be judged by payload reputation alone.
The challenge for MMAE is that DXd has changed expectations for what an ADC can accomplish in solid tumors. DXd-based platforms have demonstrated that high payload loading, potent intracellular activity and bystander effects can be combined into clinically meaningful therapeutic designs. This has pushed ADC developers to think beyond the traditional model of simply maximizing potency.
However, the success of DXd also highlights the importance of safety engineering. Greater payload delivery can increase efficacy but may also expose normal tissues to biologically active drug. The clinically recognized risk of interstitial lung disease and pneumonitis with trastuzumab deruxtecan is a clear example of why ADC development must balance tumor killing with systemic tolerability.
For this reason, "DXd is more powerful" is not sufficient as a development strategy. The relevant endpoint is the therapeutic index: how much antitumor activity can be achieved relative to toxicity, exposure and treatment limitations.
The future ADC landscape is unlikely to become a simple MMAE-versus-DXd competition. Instead, payload selection will increasingly be matched to target biology, tumor architecture and the intended therapeutic profile. New ADCs are already exploring different topoisomerase I inhibitors, next-generation auristatins and entirely different mechanisms of action.
For developers, this means that the most productive question is not "Which payload is strongest?" but "Which payload gives this particular antibody the best chance of achieving a clinically useful therapeutic window?" A moderately potent payload with excellent stability, controlled release and favorable distribution can outperform a more powerful payload that creates unacceptable systemic exposure.
MMAE therefore still has a place in ADC development—not because it can simply imitate DXd, but because it offers a different pharmacological tool. DXd has raised the competitive bar, particularly in solid tumors, but it has not eliminated the need for alternative payload mechanisms. The next generation of successful ADCs will likely come from precise matching of antibody, linker, payload, DAR and tumor biology rather than from declaring a single payload class the universal winner.
When deciding between MMAE and DXd, development teams should consider the complete product profile rather than payload potency in isolation. Target expression and internalization should be examined alongside linker stability, intracellular release, DAR, plasma exposure, bystander activity, tissue distribution and the expected resistance mechanisms.
The practical lesson is straightforward: MMAE is not losing because DXd exists, and DXd is not automatically superior because it is newer. Their value depends on the biological problem the ADC is being designed to solve. The strongest programs will be those that use payload selection as part of a rational engineering strategy rather than treating the payload as an interchangeable component.
For researchers developing next-generation ADCs, this distinction is increasingly important. As ADCs move toward more sophisticated targets, higher drug loading, site-specific conjugation and increasingly complex tumor indications, the winning molecule will be defined less by the name of its payload and more by how effectively the entire construct converts target recognition into selective tumor killing.
MMAE and DXd use fundamentally different mechanisms of cytotoxicity. MMAE is a microtubule-disrupting payload that interferes with microtubule assembly and cell division, whereas DXd is a topoisomerase I inhibitor that induces DNA damage during replication. Both are highly potent payloads, but their mechanisms can lead to different efficacy and resistance profiles depending on tumor biology.
Both MMAE and DXd can support bystander killing because their released active payloads are sufficiently membrane-permeable to affect neighboring antigen-low or antigen-negative cells. The magnitude of the bystander effect, however, depends not only on the payload but also on linker cleavage, intracellular processing, payload release and tumor distribution. Therefore, DXd should not automatically be considered superior to MMAE solely because of bystander activity.
The linker determines how effectively an ADC protects its payload during circulation and releases it after reaching the appropriate cellular environment. Cleavable linkers can facilitate release of membrane-permeable payloads and enhance bystander killing, but excessive premature cleavage may increase systemic exposure and toxicity. Consequently, the same payload can behave very differently when paired with different linker architectures.
Yes. MMAE remains a clinically validated payload and can be particularly attractive when its microtubule mechanism, membrane permeability and established conjugation chemistry fit the target biology. ADC performance depends on the integrated design of the antibody, linker, payload and drug-to-antibody ratio (DAR), rather than on payload identity alone. A well-engineered MMAE ADC may therefore achieve a favorable therapeutic window even when DXd-based platforms demonstrate strong activity in the same broader therapeutic area.
Payload selection should begin with the biological and pharmacological requirements of the intended ADC rather than simply comparing intrinsic cytotoxic potency. Key considerations include target expression and internalization, tumor heterogeneity, desired bystander activity, linker stability, DAR, intracellular release, tissue distribution and potential resistance mechanisms. The optimal payload is the one that provides the best balance between tumor exposure, antitumor activity and tolerability for the specific ADC architecture.
References
| Target | Cat. No. | Product Name | Conjugate | Application | |
| MMAE | DAG-WT669B | MMAE [BSA] | BSA | ELISA, LFIA | Inquiry |
| DAG-WT669H | MMAE [HRP] | HRP | ELISA, LFIA | Inquiry | |
| DAG-WT669 | MMAE [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT670K | Val-Cit-PAB-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT670B | Val-Cit-PAB-MMAE [BSA] | BSA | N/A | Inquiry | |
| DAG-WT684K | Mc-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT684B | Mc-MMAE [BSA] | BSA | N/A | Inquiry | |
| DAG-WT685K | MC-Val-Cit-PAB-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT685B | MC-Val-Cit-PAB-MMAE [BSA] | BSA | N/A | Inquiry | |
| DAG-WT693K | Fmoc-VC-PAB-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT693B | Fmoc-VC-PAB-MMAE [BSA] | BSA | N/A | Inquiry | |
| DAG-WT696K | DBCO-(PEG)3-VC-PAB-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT696B | DBCO-(PEG)3-VC-PAB-MMAE [BSA] | BSA | N/A | Inquiry | |
| DAG-WT697K | MAL-di-EG-Val-Cit-PAB-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT697B | MAL-di-EG-Val-Cit-PAB-MMAE [BSA] | BSA | N/A | Inquiry | |
| DAG-WT699K | N3-PEG3-VC-PAB-MMAE [KLH] | KLH | N/A | Inquiry | |
| DAG-WT699B | N3-PEG3-VC-PAB-MMAE [BSA] | BSA | N/A | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| MMAE | DEIABL312 | MMAE ADC EIA Kit | Human, Rat, Mouse, Primate | Quantitative | tissue cell cultures, serum | Inquiry |
| DEIABL314 | Intact MMAE ADC ELISA Kit | Human | Quantitative | Serum, plasma | Inquiry | |
| DEIA-JY25388 | Clivatuzumab MMAE (ADC) ELISA Kit | N/A | Quantitative | Serum, plasma | Inquiry | |
| DEIA-JY25414 | Trastuzumab MMAE (ADC) ELISA Kit | N/A | Quantitative | Serum, plasma | Inquiry | |
| DEIA-JY25422 | Atezolizumab-MMAE (ADC) ELISA Kit | N/A | Quantitative | Serum, plasma | Inquiry |
Loading ......